None
Quote | Cel-Sci Corporation (NYSE:CVM)
Last: | $1.53 |
---|---|
Change Percent: | 2.0% |
Open: | $1.54 |
Close: | $1.50 |
High: | $1.5599 |
Low: | $1.53 |
Volume: | 14,615 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Cel-Sci Corporation (NYSE:CVM)
CEL-4000 may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weakening important immune defense mechanisms, risking infections or cancer, as current treatments may CEL-SCI Corporation (NYSE American: CVM) today announced the peer rev...
2024-02-15 08:10:32 ET More on Cel-Sci Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA CEL-SCI spikes as U.K. picks cancer drug, Multikine for review Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Finan...
Message Board Posts | Cel-Sci Corporation (NYSE:CVM)
Subject | By | Source | When |
---|---|---|---|
So are you no longer in either? Just | renaissance1 | investorshub | 04/30/2023 3:07:58 AM |
Sold my 90k in the $2s last may Cheers | sushifishman | investorshub | 04/29/2023 11:04:41 PM |
Hi Hogg | sushifishman | investorshub | 04/29/2023 10:59:03 PM |
for some reason he's way more triggered about | tarius729 | investorshub | 04/29/2023 9:36:04 PM |
Sushi. Are you still in$ NWBO? They seem | renaissance1 | investorshub | 04/29/2023 3:36:22 AM |
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
NYSE Market:
CEL-4000 may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weakening important immune defense mechanisms, risking infections or cancer, as current treatments may CEL-SCI Corporation (NYSE American: CVM) today announced the peer rev...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: CEL-SCI identified the target head and neck cancer patient popul...
CEL-SCI Corporation (NYSE American: CVM) , a phase 3 cancer-immunotherapy company, has closed on its previously announced public offering. The offering was comprised of 3,875,000 shares of common stock, offered at $2 per share, resulting in $7.75 million in gross proceeds before deducting underwr...